These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 9934481)

  • 21. Design and synthesis of novel conformationally restricted HIV protease inhibitors.
    Salituro FG; Baker CT; Court JJ; Deininger DD; Kim EE; Li B; Novak PM; Rao BG; Pazhanisamy S; Porter MD; Schairer WC; Tung RD
    Bioorg Med Chem Lett; 1998 Dec; 8(24):3637-42. PubMed ID: 9934485
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stereoisomers of cyclic urea HIV-1 protease inhibitors: synthesis and binding affinities.
    Kaltenbach RF; Nugiel DA; Lam PY; Klabe RM; Seitz SP
    J Med Chem; 1998 Dec; 41(25):5113-7. PubMed ID: 9836627
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of N-methylpiperazine for the preparation of piperazine-based unsymmetrical bis-ureas as anti-HIV agents.
    El-Faham A; Armand-Ugón M; Esté JA; Albericio F
    ChemMedChem; 2008 Jul; 3(7):1034-7. PubMed ID: 18383064
    [No Abstract]   [Full Text] [Related]  

  • 24. Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450.
    Hodge CN; Aldrich PE; Bacheler LT; Chang CH; Eyermann CJ; Garber S; Grubb M; Jackson DA; Jadhav PK; Korant B; Lam PY; Maurin MB; Meek JL; Otto MJ; Rayner MM; Reid C; Sharpe TR; Shum L; Winslow DL; Erickson-Viitanen S
    Chem Biol; 1996 Apr; 3(4):301-14. PubMed ID: 8807858
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantitative structure-activity relationship by CoMFA for cyclic urea and nonpeptide-cyclic cyanoguanidine derivatives on wild type and mutant HIV-1 protease.
    Avram S; Bologa C; Flonta ML
    J Mol Model; 2005 Mar; 11(2):105-15. PubMed ID: 15714296
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel azacyclic ureas that are potent inhibitors of HIV-1 protease.
    Sham HL; Zhao C; Marsh KC; Betebenner DA; Lin S; Rosenbrook W; Herrin T; Li L; Madigan D; Vasavanonda S; Molla A; Saldivar A; McDonald E; Wideburg NE; Kempf D; Norbeck DW; Plattner JJ
    Biochem Biophys Res Commun; 1996 Aug; 225(2):436-40. PubMed ID: 8753780
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Computational design of new cyclic urea inhibitors for improved binding of HIV-1 aspartic protease.
    Kotamarthi B; Bonin I; Benedetti F; Miertus S
    Biochem Biophys Res Commun; 2000 Feb; 268(2):384-9. PubMed ID: 10679213
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis, stability, antiviral activity, and protease-bound structures of substrate-mimicking constrained macrocyclic inhibitors of HIV-1 protease.
    Tyndall JD; Reid RC; Tyssen DP; Jardine DK; Todd B; Passmore M; March DR; Pattenden LK; Bergman DA; Alewood D; Hu SH; Alewood PF; Birch CJ; Martin JL; Fairlie DP
    J Med Chem; 2000 Sep; 43(19):3495-504. PubMed ID: 11000004
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cyclic HIV protease inhibitors: synthesis, conformational analysis, P2/P2' structure-activity relationship, and molecular recognition of cyclic ureas.
    Lam PY; Ru Y; Jadhav PK; Aldrich PE; DeLucca GV; Eyermann CJ; Chang CH; Emmett G; Holler ER; Daneker WF; Li L; Confalone PN; McHugh RJ; Han Q; Li R; Markwalder JA; Seitz SP; Sharpe TR; Bacheler LT; Rayner MM; Klabe RM; Shum L; Winslow DL; Kornhauser DM; Hodge CN
    J Med Chem; 1996 Aug; 39(18):3514-25. PubMed ID: 8784449
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and antiviral activity of P1' arylsulfonamide azacyclic urea HIV protease inhibitors.
    Huang PP; Randolph JT; Klein LL; Vasavanonda S; Dekhtyar T; Stoll VS; Kempf DJ
    Bioorg Med Chem Lett; 2004 Aug; 14(15):4075-8. PubMed ID: 15225729
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis and Biological Evaluation of 3,9-Dioxatetraasteranes as C
    Li P; Wang S; Wang H; Yan H
    Biol Pharm Bull; 2019; 42(2):261-267. PubMed ID: 30713256
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti HIV-1 agents 6. Synthesis and anti-HIV-1 activity of indolyl glyoxamides.
    Wang Y; Huang N; Yu X; Yang LM; Zhi XY; Zheng YT; Xu H
    Med Chem; 2012 Sep; 8(5):831-3. PubMed ID: 22741604
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular basis of HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with cyclic urea inhibitors.
    Ala PJ; Huston EE; Klabe RM; McCabe DD; Duke JL; Rizzo CJ; Korant BD; DeLoskey RJ; Lam PY; Hodge CN; Chang CH
    Biochemistry; 1997 Feb; 36(7):1573-80. PubMed ID: 9048541
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibitory effect of triterpenes from Crataegus pinatifida on HIV-I protease.
    Min BS; Jung HJ; Lee JS; Kim YH; Bok SH; Ma CM; Nakamura N; Hattori M; Bae K
    Planta Med; 1999 May; 65(4):374-5. PubMed ID: 10364847
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Photochemical Route to Optically Active Hexahydro-4
    Ghosh AK; Robinson WL
    J Org Chem; 2019 Aug; 84(15):9801-9805. PubMed ID: 31310117
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Advances in novel anti-HIV-1 drugs and drug candidates: 2005-2008].
    Zheng PR; Xue H; Xiao ZY; Liu G
    Yao Xue Xue Bao; 2010 Feb; 45(2):154-64. PubMed ID: 21351426
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polyoxometalate HIV-1 protease inhibitors. A new mode of protease inhibition.
    Judd DA; Nettles JH; Nevins N; Snyder JP; Liotta DC; Tang J; Ermolieff J; Schinazi RF; Hill CL
    J Am Chem Soc; 2001 Feb; 123(5):886-97. PubMed ID: 11456622
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Can cyclic HIV protease inhibitors bind in a non-preferred form? An ab initio, DFT and MM-PB(GB)SA study.
    Oehme DP; Brownlee RT; Wilson DJ
    J Mol Model; 2013 Mar; 19(3):1125-42. PubMed ID: 23149763
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Counteracting HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with XV638 and SD146, cyclic urea amides with broad specificities.
    Ala PJ; Huston EE; Klabe RM; Jadhav PK; Lam PY; Chang CH
    Biochemistry; 1998 Oct; 37(43):15042-9. PubMed ID: 9790666
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Accessing HIV-1 Protease Inhibitors through Visible-Light-Mediated Sequential Photocatalytic Decarboxylative Radical Conjugate Addition-Elimination-Oxa-Michael Reactions.
    Krolo T; Bhattacharyya A; Reiser O
    Org Lett; 2021 Aug; 23(16):6283-6287. PubMed ID: 34347496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.